A Study of HS-20110 in Participants With Advanced Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
Recruiting
- Brcr Medical Center Inc
Tamarac, Florida, United States
Chintan Gandhi, MDRecruiting - Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, United States
Sunil BabuRecruiting - Carolina Biooncology Institute
Huntersville, North Carolina, United States
John PowderlyRecruiting - the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Siqing Fu, MDRecruiting - Next Dallas
Irving, Texas, United States
Michael SongRecruiting - Next Oncology
San Antonio, Texas, United States
David SomerhalderRecruiting - Next Virginia
Fairfax, Virginia, United States
Alexander SpiraRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 26 Feb 2025
- Primary completion
- 31 Dec 2026
- Completion
- 30 Sept 2027
- Last update posted
- 20 Apr 2026
- Registered enrollment
- 475
- Registry id
- NCT06892379
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.